
Asia Frontier Pharmaceuticals LimitedAsia Frontier Pharmaceuticals Limited is a pharmaceutical trading and service enterprise focused on anti-tumor drugs and innovative drug accessibility solutions. Based in Asia and serving the globe, we are committed to providing patients with safe, effective, and affordable high-quality medicines, narrowing the medication gap across different regions and populations.The Problem We AddressIn the current healthcare system, many patients face the following dilemmas:Having a clear treatment plan but being unable to afford the medication.A significant gap exists between clinical guidelines and patients' ability to pay.The goal of Asia Frontier Pharmaceuticals is not to "sell more drugs," but to ensure that patients in genuine need have access to and can afford the right medicines.Core Business FocusAnti-tumor Drugs (Solid Tumors/Hematologic Malignancies) Targeted Therapy Innovative and Specialized Drugs Infectious Disease-related Pharmaceuticals International Trade and Regional Supply of Pharmaceutical ProductsCompany MissionTo make life-saving medicines affordable for every patient.We are dedicated to bridging the ...
year Industry R & D experience
item Business coverage area
+ invention patent
+ Industry Solutions

2020-07-21Cancer Degree Express, December 30, 2025: A Review of 2025‘s Milestone Advances in Cancer Therapy—Targeted Protein Degraders and Antibody-Drug Conjugates Make the List
2020-07-21New research: Big step toward targeted molecular therapies for cancer
2020-07-21Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
2020-07-21In the early 1980s, the development and application of antisense oligonucleotides that could specifically bind to messenger RNA (mRNA) and inhibit protein synthesis represented a groundbreaking advancement in molecular biology.
2020-07-21Two new studies represent a big step toward developing innovative molecular therapies capable of disrupting the uncontrollable growth of cancers at their roots.
2020-07-21MGC and Veritas In Silico Sign MOU for Joint Venture in the Development of RNA-Targeted Pharmaceuticals

Therapeutic drugs are agents that directly target the cause, pathological process, or symptoms of a disease, aiming to cure the illness, control its progression, or alleviate key symptoms. They work through specific mechanisms, such as antibiotics killing bacteria or anticancer drugs targeting tumor cells. These drugs typically have clear actions and a relatively rapid onset, forming the core component of treatment regimens.
Adjuvant drugs may not directly target the cause of a disease but play a role in enhancing the efficacy of primary treatments, reducing their side effects, or supporting the body's tolerance. Examples include antiemetics or drugs to boost white blood cell count during cancer chemotherapy, and nutritional support drugs perioperatively. They do not treat the primary disease directly but are crucial for ensuring the smooth implementation of main treatment plans and patient recovery.
Preventive drugs are primarily used to prevent the occurrence or recurrence of diseases. They work by activating the immune system against infections (e.g., vaccines), supplementing deficient substances to prevent related disorders (e.g., Vitamin D for rickets), or long-term use to reduce chronic disease risks (e.g., low-dose aspirin for cardiovascular events). Their core value lies in "preventing trouble before it happens," lowering the probability of falling ill.
Conditioning drugs focus on holistically improving bodily functions and balancing internal states, rather than directly attacking specific pathogens. They are commonly used to regulate physiological functions (e.g., hormonal balance, immune function), improve suboptimal health, or aid the body's recovery. Examples include traditional Chinese medicine膏方 (herbal paste) for nourishing and strengthening the body. Their effects are generally more gentle and gradual, aiming to help the body establish long-term health equilibrium.

核心要点疗法类型:抗体偶联siRNA(AOC 1001, delpacibart etedesiran),一种将靶向siRNA与抗体结合的新型疗法。治疗领域:1型肌强直性营养不良(DM1),一种由DMPK基因突变引起的罕见遗传性神经肌肉病。

衰老并非一条平滑的直线,而是在特定年龄段可能出现“加速期”。研究发现,人体在 30岁左右 和 45~55岁 会经历两次明显的“断崖式衰老”。这意味着,养生抗衰的关键在于 30岁前打好基础,45岁后加强维护。越早养成良好习惯,越能将衰老的“拐点”推后,让外表和身体状态都更年轻。

The information related to antineoplastic drugs provided on this platform is intended solely for medical and science communication purposes and does not constitute diagnosis, treatment, or medication recommendations.
Physicians on this platform do not participate in the sale, recommendation, or prescribing decisions related to any pharmaceutical products.
Our company guarantees the quality of all products sold, but does not provide any guarantee of therapeutic efficacy. Patients should make their own decisions after fully understanding the risks and shall bear the corresponding responsibilities accordingly.
Company Name:
Asian Frontier Pharmaceutical Information Co., Ltd.
Hotline:
+86 13382285011
Company address:
No. 88, Moumou Industrial Zone, Tianhe District, Guangzhou City, Guangdong Province
E-mail address:
504051920@qq.com
Code
Copyright © 2018-2026 Asian Frontier Pharmaceutical Information Co., Ltd. All rights reserved sitemap.xml